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Abstract
Abnormalities in the STAT3 pathway are involved in the oncogenesis of several cancers. However, the mechanism
by which dysregulated STAT3 signaling contributes to the progression of human colorectal cancer (CRC) has not
been elucidated, nor has the role of JAK, the physiological activator of STAT3, been evaluated. To investigate the
role of both JAK and STAT3 in CRC progression, we inhibited JAK with AG490 and depleted STAT3 with a SiRNA.
Our results demonstrate that STAT3 and both JAK1 and 2 are involved in CRC cell growth, survival, invasion, and
migration through regulation of gene expression, such as Bcl-2, p16ink4a, p21waf1/cip1, p27kip1, E-cadherin, VEGF,
and MMPs. Importantly, the FAK is not required for STAT3-mediated regulation, but does function downstream of
JAK. In addition, our data show that proteasome-mediated proteolysis promotes dephosphorylation of the JAK2,
and consequently, negatively regulates STAT3 signaling in CRC. Moreover, immunohistochemical staining reveals
that nuclear staining of phospho-STAT3 mostly presents in adenomas and adenocarcinomas, and a positive cor-
relation is found between phospho-JAK2 immunoreactivity and the differentiation of colorectal adenocarcinomas.
Therefore, our findings illustrate the biologic significance of JAK1, 2/STAT3 signaling in CRC progression and pro-
vide novel evidence that the JAK/STAT3 pathway may be a new potential target for therapy of CRC.
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Introduction
The Janus kinase ( JAK)/signal transducer and activator of transcrip-
tion (STAT) signaling pathway plays a significant role in various
physiological processes, including immune function, cell growth, dif-
ferentiation, and hematopoiesis [1]. Recently, accumulating evidence
indicates that abnormalities in the JAK/STAT pathway are involved
in the oncogenesis of several cancers. For example, Lacronique and
coworkers [2] reported that constitutive activation of JAK2 was
found in childhood T cell acute lymphoblastic leukemia. Constitu-
tive activation of signal transducer and activator of transcription 3
(STAT3) correlates with cell proliferation in breast carcinoma [3] and
non–small cell lung cancer [4], and also inhibits apoptosis [5–7]. Con-
versely, inhibition of JAK/STAT signaling suppresses cancer cell growth
and induces apoptosis in various cancers [3,8–12]. Recent studies have
also revealed that altered STAT3 activation can contribute to oncogen-
esis. For example, activation of STAT3 is required for cell transforma-
tion by oncogenic Src [13] and by a constitutively active form of Gαo,
a heterotrimeric G-protein subunit [14]. These published reports all
demonstrate the crucial importance of the JAK/STAT pathway in tu-
morigenesis and progression.
Colorectal cancer (CRC) is a very common malignancy and one of
the leading causes of morbidity and death in the world. Despite our
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dothelial growth factor
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growing understanding of oncogenesis and successful identification
of protooncogenes and tumor suppressor genes involved in the tu-
morigenesis of CRC, the biologic and molecular mechanisms in
CRC are poorly understood. In general, the molecular mechanisms
that control CRC progression are related to the altered expression of
different protooncogenes, tumor suppressor genes, cytokines, and
their receptors, including Ras, Src, p27kip1, p16ink4a, interleukin,
and epidermal growth factor receptor [15–21]. Notably, these abnor-
malities involve the JAK/STAT signal transduction pathway. In fact,
STAT3 is constitutively activated in various types of human tumors,
including colorectal cancer, but very few studies have reported abnor-
mal expression or activation of JAK/STAT in CRC [22]. Ma and
coworkers showed that the level of activated phospho-STAT3
(pSTAT3) increased in 45 primary CRC samples compared to adja-
cent normal mucosae [23]. A significant correlation was also demon-
strated between STAT3 and both survivin and Bcl-xl expression in
CRC [24]. However, the role of STAT3 in the pathogenesis of
CRC has not been examined fully. In addition, the function of
JAK, the physiological activator of STAT3, in stimulating STAT3
in CRC cells remains unclear.
To directly assess the biologic significance of JAK/STAT3 signal-
ing in CRC, using AG490, a pharmacological inhibitor of JAK,
and small interfering RNA (siRNA) to deplete STAT3 in two human
CRC cell lines (SW1116 and HT29), we investigated the changes
in cell viability, apoptosis, cell cycle progression, and cell invasive ca-
pability. We also evaluated the changes in the expression of several
proteins that directly relate to apoptosis (Bcl-2 and survivin), cell
cycle regulation (p16ink4a, p21waf1/cip1, and p27kip1), and cell inva-
sion (matrix metalloproteinase 2 [MMP2], 9 [MMP9], vascular en-
dothelial growth factor [VEGF], focal adhesion kinase [FAK], and
E-cadherin). In addition, we also examined the expression of STAT3,
JAK2, and their active phosphorylated forms in normal colonic epi-
thelium, adenomas, and primary colon adenocarcinomas. Our aim
was to determine the role of JAK/STAT3 signaling in CRC progres-
sion and test the hypothesis that JAK/STAT3 signaling could serve as
therapeutic targets.
Materials and Methods
Cell Culture, Treatment with Pharmacologic Agents, and
Transient Transfection of STAT3 siRNA
Two human colorectal cancer cell lines (SW1116 and HT29) were
used in this study, cultured in RPMI 1640 medium (Gibco, Carlsbad,
CA) or McCoy’s 5A medium (Sigma, St. Louis, MO), respectively,
supplemented with 10% fetal bovine serum at 37°C in a humidified
5% CO2 atmosphere.
Both pharmacological inhibitors were purchased from Sigma.
AG490, a pharmacological JAK2 inhibitor, was dissolved in ethanol
and stored at −20°C until used. It was added at 16 to 24 hours after
the cells were seeded at a final concentration of 0, 50, 100, and
150 μM. MG132, a pharmacological proteasome inhibitor, was dis-
solved in dimethyl sulfoxide and stored −20°C. At the time of the
experiment, an aliquot of MG132 was thawed and diluted with tis-
sue culture media to a final concentration of 10 μM.
Commercial STAT3 siRNA was obtained from Dharmacon Inc.
(Lafayette, CO) and used to target human STAT3 (GenBank Acces-
sion Number: NM_003150). Cells were transfected with siRNA
(50 nM) by using the DharmaFECT 1 siRNA transfection reagent
according to the manufacturer’s instructions. Nonspecific siRNA
(Dharmacon Inc.) was used as a negative control, and the selective
silencing of STAT3 was confirmed by Western blot analysis.
Western Blot and Antibodies
Western blot analysis was performed using standard techniques as
described previously [25]. Briefly, the cells were lysed in M-PER Re-
agent (Pierce, Rockford, IL) containing protease inhibitors. Equal
amounts of protein (50-200 μg/lane) from whole-cell lysates were sub-
jected to sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
After that, proteins were transferred to nitrocellulose (Amersham,
Amersham, UK) and were probed with specific primary antibodies,
and then with the appropriate HRP-conjugated secondary antibodies
(Pierce). Proteins were detected using the enhanced chemilumines-
cence detection kit (SuperSignal West Femto Substrate; Pierce). For
loading control, the membrane was probed with a monoclonal anti-
body for glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Antibodies used in this study were purchased from Cell Signaling Tech-
nology Inc., unless otherwise specified: pJAK3Tyr980 (Santa Cruz, CA),
Bcl-2 (R&D Systems, Minneapolis, MN), and GAPDH (Kangchen,
Shanghai, China). All primary antibodies were used at a 1:1000 dilution.
Cell Viability Assay
Cell viability was assessed by a tetrazolium salt (WST-8)–based
colorimetric assay in the Cell Counting Kit 8 (CCK-8; Dojindo,
Kumamoto, Japan) [26,27]. Briefly, control and treated CRC cells
were seeded onto 96-well plates at an initial density of 5 × 103 cells/
well. At specified time points, 10 μl of CCK-8 solution was added to
each well of the plate. Then the plate was incubated for 1 hour. Cell
viability was determined by scanning with a microplate reader at
450 nm. Data were expressed as the percentage of viable cells as follows:
relative viability (%) = [A450(treated) − A450(blank)]/[A450(control) −
A450(blank)] × 100%.
Cell Cycle Analysis Using Propidium Iodide and
Flow Cytometry
Approximately 1 × 106 cells were removed at specified time points,
washed twice with PBS and fixed in cold ethanol for 30 min, and
then incubated with propidium iodide (PI) for 30 minutes. There-
after, cells were analyzed by a flow cytometer (BD, San Diego, CA).
Detection of Apoptosis
Apoptosis was determined by two methods. For nuclear morphol-
ogy, cells were fixed and stained with Hoechst 33258 according to
the manufacturer’s instruction (Beyotime, Beijing, China). Then
stained nuclei were observed immediately under a fluorescence mi-
croscope (Nikon, Tokyo, Japan). For flow cytometry analysis, an
annexin-V fluorescein isothiocyanate/PI double-stain assay was per-
formed in accordance with the manufacturer’s protocol (BioVision,
Mountain View, CA). Briefly, after treatment, both floating and tryp-
sinized adherent cells (5 × 105) were collected and resuspended in
500 μl of binding buffer containing 5 μl of annexin-V fluorescein
isothiocyanate and 5 μl of PI, then incubated for 5 minutes in the
dark at room temperature. Analysis was immediately performed using
a flow cytometer.
In Vitro Invasion Assay
Cell invasion assay was performed as described by Hecht et al.
[28]. In brief, chambers with 8-μm-pore polycarbonate membranes,
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coated with Matrigel on the upper side, were used (Becton-Dickinson,
San Diego, CA). Cells were transfected with STAT3 siRNA (50 nM)
for 48 hours. And then 1 × 105 transfected cells were harvested and
seeded in serum-free medium into the upper chamber, whereas medium
supplemented with 10% fetal bovine serum was applied to the low-
er chamber as a chemoattractant to induce invasion. Cells trans-
fected with nonspecific siRNA were used as the negative control.
After incubation for 24 hours, nonmigrated cells on the upper
chamber of the filter were removed with a cotton swab. Migrated
cells on the bottom surface of the filter were fixed, stained and
counted. To investigate the inhibitory effects of AG490, the upper
chamber was filled with 100 μM AG490 or ethanol at an equiva-
lent volume (as a vehicle control), respectively.
ELISA Analysis of VEGF, MMP2, and MMP9 Release
Cells (1 × 105) transfected with STAT3 siRNA (50 nM) were
maintained in serum-free medium for 48 hours. The medium was
collected, and the concentrations of VEGF, MMP2, and MMP9 in
the medium were determined using an ELISA kit (R&D Systems)
according to the manufacturer’s instruction. To investigate the inhib-
itory effects of AG490, 1 × 105 cells were cultured in 24-well culture
plates until 90% confluence. Then the spent medium was removed,
dishes were washed three times and incubated with serum-free me-
dium containing AG490 or an equivalent volume of ethanol (vehicle
control) for 24 hours. Thereafter, the medium was collected and as-
sessed for all three proteins.
Tissue Microarray and Immunohistochemical Staining
All specimens were from patients (38 primary colorectal adeno-
carcinomas and 46 adenomas) who underwent surgery in Shanghai
Renji Hospital from July 2005 to January 2007. The protocol had
the approval of the ethics committee of Shanghai Jiao-Tong Univer-
sity School of Medicine Renji Hospital and the research was carried
out according to the provisions of the Helsinki Declaration of 1975.
None of the patients received preoperative treatments such as radio-
therapy or chemotherapy. Each adenocarcinoma was assigned a
histologic type according to the World Health Organization classifi-
cation as follows: well-differentiated adenocarcinoma, moderately
differentiated adenocarcinoma, poorly differentiated adenocarci-
noma, and mucinous adenocarcinoma. Meanwhile, 15 specimens
of normal colonic epithelium, taken from patients without colorectal
cancer, were used as a negative control. A tissue microarray (diameter,
1.0 mm; depth, 4 μm) was prepared by Outdo Biotech (Shanghai,
China) using standard techniques [29].
The tissue microarray sections were deparaffinized in xylene and rehy-
drated using a graded series of ethanol. A three-step streptavidin-biotin-
horseradish peroxidase method was used, and the expressions of STAT3,
pSTAT3Tyr705, JAK2, and phospho-JAK2 (pJAK2)Tyr1007/Tyr1008 were
examined with the primary antibodies (STAT3, dilution 1:100;
pSTAT3Tyr705, JAK2, and pJAK2Tyr1007/Tyr1008, dilution 1:50) using
the LSAB+ kit (DakoCytomation, Copenhagen, Denmark) according
to the manufacturer’s instructions.
The slides were examined independently by two investigators
blinded to both clinical and pathologic data. Protein expression
was quantified based on the extent of staining (percentage of pos-
itive tumor cells) and classified into two categories: negative,
0% to 15% positive tumor cells; positive, more than 15% positive
tumor cells.
Statistical Analysis
Results were expressed as the mean ± SD. The data were analyzed
for significance by analysis of variance. Analyses comparing the ex-
pression of STAT3, JAK2, and their active forms were performed using
chi-square analysis, and results were considered significant if the P value
was less than 0.05.
Results
AG490 and RNAi Induce Downregulation of JAK1,
2/STAT3 Signaling
Western blot analysis showed a concentration-dependent decrease
in the expression of JAK2 and pJAK2 24 hours after treatment with
AG490 (Figure 1A). pJAK2 was almost undetectable at a concentra-
tion of 150 μM AG490. Meanwhile, AG490 exposure also decreased
in JAK1 and pJAK1 levels in both CRC cell lines. But both JAK2
and pJAK2 were more markedly downregulated by AG490 treatment
than JAK1 and pJAK1. Nevertheless, no significant changes in the
JAK3 and pJAK3 levels were seen by AG490 treatment in our study.
Therefore, our data suggest that whereas both JAK1 and JAK2 may
contribute to abnormalities in JAK/STAT signaling in CRC tumori-
genesis and progression, JAK2 might play a more important role. In
addition, AG490 decreased the pSTAT3 levels in a concentration-
dependent manner in SW1116 and HT29 cells after 24 hours of
exposure. However, no detectable changes in the STAT3 level were
seen in AG490-treated cells, implying that another pathway is
responsible for the activation of STAT3. To selectively reduce the
expression of STAT3, we used a siRNA. Western blot analysis re-
vealed that both STAT3 and pSTAT3 (thus activated) were depleted
by 59.8% and 80.3% in STAT3 silenced HT29 cells, respectively
(Figure 1B).
The Proteasome Inhibitor, MG132, Inhibits AG490-Induced
Downregulation of pJAK2 and pSTAT3
To test if the proteasome inhibitor, MG132, can inhibit the
AG490-induced downregulation of the total JAK1 and JAK2 protein
levels, both SW1116 and HT29 cells were incubated in the presence
of 100 μM AG490 for 16 hours, treated with MG132 (10 μM)
and harvested at 0, 4, or 8 hours later. As seen in Figure 1C, although
no detectable changes in JAK1, pJAK1, or JAK2 levels were seen,
pJAK2 expression, which was low after 16 hours of AG490 treat-
ment, increased in a time-dependent manner. Furthermore, the
level of pSTAT3 increased in cells exposed to MG132. These results
demonstrate that the proteasome inhibitor MG132 prevents dephos-
phorylation of the JAK2 kinase, and results in the activation of
downstream STAT3 protein.
Disruption of JAK1, 2/STAT3 Signaling Is Associated with the
Modulation of Some Downstream STAT3 Targets
We further examined the expression of various apoptosis and cell
cycle regulatory proteins known to be downstream targets of the
STAT3 pathway. At 24 hours, increased doses of AG490 induced
downregulation of Bcl-2 simultaneously with upregulation of p16ink4a,
p21waf1/cip1, and p27kip1 in SW1116 cells (Figure 2A). However, no
change was seen at the protein level for survivin. The overall pattern
was similar for HT29 cells, although the upregulation was more
marked (Figure 2A, right panel ). In addition, STAT3 downregulation
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by siRNA induced similar effects. At 72 hours posttransfection (Fig-
ure 2B), including downregulation of Bcl-2 and upregulation of p16ink4a,
p21waf1/cip1, and p27kip1.
Inhibition of JAK1, 2/STAT3 Signaling by AG490 or siRNA
Suppresses CRC Cell Growth
As detected by the CCK-8 assay (Figure 3A), after 24 hours of
treatment, AG490 induced a concentration-dependent decrease in
the number of viable SW1116 and HT29 cells. Similarly, our results
indicated that RNAi-induced STAT3 deficiency inhibited CRC cell
growth. This suppression lasted for 72 hours, and the cells recovered
96 hours posttransfection (Figure 3A).
Inhibition of JAK1, 2/STAT3 Pathway Induces G1 Cell Cycle
Arrest and Apoptosis
To explore the reason for the decrease in cell viability, we examined
the effects of JAK1, 2/STAT3 signaling on cell cycle progression and
apoptosis. As illustrated in Figure 3B, pretreatment of CRC cells with
AG490 and STAT3 siRNA blocked the cell cycle in the G1 phase.
Furthermore, a dose-dependent G1 cell cycle arrest was also found in
Figure 1. AG490 and STAT3 siRNA downregulation of JAK1, 2/STAT3 signaling. (A) Western blot analysis revealed that AG490 induced a
concentration-dependent decrease in JAK2 and pJAK2 levels at 24 hours in CRC cells. In the same experiment, decreases in JAK1,
pJAK1, and pSTAT3 levels were also identified, although the decrease in JAK3, pJAK3, and STAT3 was not statistically significant.
(B) At 72 hours posttransfection, Western blot analysis showed that STAT3 siRNA induced downregulation of STAT3 and pSTAT3 in
CRC cells. (C) MG132 blocks downregulation of pJAK2 and pSTAT3, induced by AG490. SW1116 and HT29 cells incubated with AG490
for 16 hours were treated with MG132, a proteasome inhibitor. MG132 induced a time-dependent upregulation of pJAK2 and pSTAT3.
The data shown are representative of three separate experiments. GAPDH was used for the loading control. Quantification of the target
protein bands relative to GAPDH is shown in the right panel.
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AG490-treated cells (Figure 3B). In SW1116 cells, for example, the
G0/G1–phase fraction increased from 38.2% (untreated) to either
52.3%, 63.9%, or 72.3%, at 50, 100, or 150 μM AG490, respec-
tively. These observations are consistent with upregulation of
p16ink4a, p21waf1/cip1, and p27kip1 expression, suggesting that the
JAK1, 2/STAT3 pathway is involved in cell cycle regulation.
To evaluate whether the decrease in cell viability might have occurred
due to apoptotic cell death, we first examined nuclear morphology by
staining the cells with Hoechst 33258 after treatment with AG490.
SW1116 cells stained with Hoechst 33258 showed typical morphologic
features of apoptosis including nuclear condensation and/or fragmenta-
tion 24 hours after treatment with 100 μM AG490 (Figure 3C ).
To quantify apoptotic cell death, we performed flow cytometry
analysis (Figure 3C ). After 24 hours of AG490 treatment, phospha-
tidylserine extrusion to the outer leaflet of the plasma membrane, as
detected by annexin-V binding to the surface of SW1116 cells in-
creased. Our studies demonstrated that there was a 3.33-fold increase
in apoptotic SW1116 cells after 24 hours of treatment with 100 μM
AG490. Similarly, a 4.8-fold increase in apoptotic HT29 cells was
also detected. STAT3 siRNA induced similar effects. At 72 hours
after transfection with 50 nM of STAT3 siRNA, the apoptosis
of SW1116 and HT29 cells increased 2.55- and 3.50-fold, respec-
tively, when compared with the equivalent transfection with nonspe-
cific siRNA.
Figure 2. Disruption of JAK1, 2/STAT3 signaling is associated with modulation of some STAT3 downstream targets. (A) Western blot
analysis showed that AG490 induced concentration-dependent alterations of part, but not all, of the STAT3 downstream targets in
SW1116 cells at 24 hours after treatment. Bcl-2 was downregulated, simultaneously associated with the upregulation of p16ink4a,
p21waf1/cip1, and p27kip1, whereas survivin showed no detectable change. A similar pattern of changes was identified in HT29 cells.
(B) STAT3 siRNA induced similar effects. Indeed, downregulation of Bcl-2, and upregulation of p16ink4a, p21waf1/cip1, and p27kip1 were
detected at 72 hours after transfection of the cells. GAPDH was used for the loading control. Quantification of the target protein bands
relative to GAPDH is shown in the right panel.
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Disruption of JAK1, 2/STAT3 Signaling Inhibits Colorectal
Cancer Cells Invasion
We next addressed the functional role of JAK1, 2/STAT3 signaling
in the invasion of the cells into the surrounding tissue. As shown in
Figure 4A, AG490 treatment suppressed cell invasion. The number
of cells that migrated through the filter decreased to 73.5% in HT29
cells after 24 hours of treatment with 100 μM AG490 when com-
pared to ethanol-treated (vehicle control) cells, demonstrating a po-
tential regulatory role of JAK/STAT signaling on the invasive
capability of CRC cells.
To verify if this inhibitory effect was mediated by STAT3, we used
siRNA to specifically knockdown STAT3 expression. As illustrated in
Figure 4B, STAT3 siRNA, but not nonspecific siRNA, effectively
suppressed CRC cell invasion. Forty-eight hours after transfection
with 50 nM of STAT3 siRNA, the number of SW1116 and
HT29 cells that migrated through the filter decreased to 57.4%
and 47.5%, respectively, when compared to cells transfected with
nonspecific siRNA. These results indicate that STAT3 is a critical
mediator involved in JAK/STAT–induced cell invasion.
Decreased STAT3 Activation Is Associated with Modulation of
E-cadherin, MMP2, and VEGF, But Not FAK and MMP9
To better understand the mechanisms of JAK1, 2/STAT3 signaling
on CRC cell invasion and to reveal downstream events of JAK/
STAT3 signaling that are involved in the regulation of cell invasion,
we examined the expression of various migration and invasion regu-
latory proteins by Western blot and ELISA analyses. As shown in Fig-
ure 4, F and E, STAT3 siRNA and increasing doses of AG490 reduced
secretion of MMP2 and VEGF, while upregulating E-cadherin expres-
sion in CRC cells (Figure 4,D and C ). However, no significant change
in MMP9 secretion was seen in cells treated with either STAT3 RNAi
or AG490 treatment (Figure 4, E and F ).
Interestingly, although no detectable changes in the expression of
FAK were seen by STAT3 siRNA transfection (Figure 4D), AG490
induced downregulation of the total FAK protein level in both
SW1116 and HT29 cells (Figure 4C ) in a dose-dependent manner.
Our studies imply that: (1) FAK is not required for STAT3-mediated
regulation; and that (2) FAK may be a component of the JAK path-
way, downstream of JAK.
Figure 3. The functional role of JAK1, 2/STAT3 signaling on CRC cell growth, cell cycle progression, and apoptosis. (A) Cell viability as
determined by the CCK-8 assay of CRC cells treated with AG490 or STAT3 siRNA. SW1116 cells were treated with solvent only (negative
controls) or with 50, 100, or 150 μM AG490. The percentage of viable cells was determined as described in the Materials and Methods
section. AG490 significantly decreased the number of viable cells. No significant difference was seen in the three dosages of AG490.
Treating HT29 cells with AG490 also induced a concentration-dependent decrease in the number of viable cells at 72 hours. In addition,
STAT3 siRNA inhibited CRC cell growth. This suppression lasted for 72 hours, and the cell recovered at 96 hours posttransfection. The
results represent mean ± SD of three experiments. (B) Cell cycle analysis was performed using SW1116 cells treated with diluent (left)
or AG490 (50, 100, or 150 μM) for 24 hours. Compared to the negative control, our results reveal that AG490 induces a concentration-
dependent increase in the proportion of cells in the G1 phase. Moreover, treating SW1116 cells with STAT3 siRNA blocked the cell cycle
in the G1 phase at 72 hours after transfection. (C) CRC cells was treated with 100 μM AG490 for 24 hours or STAT3 siRNA for 72 hours,
and cell apoptosis was detected by morphologic changes and flow cytometric analysis.
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Activated STAT3 Is Constitutively Expressed in
Colorectal Carcinoma
Table 1 shows the frequency of expression of STAT3, pSTAT3,
JAK2, and pJAK2 by immunohistochemical staining. STAT3 expres-
sion was detected in 86.7% of the normal colonic epithelium sam-
ples, 89.1% of the adenoma samples, and 100% of the primary colon
adenocarcinoma samples. STAT3 staining was detected mainly in the
cytoplasm, with occasional nuclear staining. However, pSTAT3 ex-
pression, mostly presented in the nucleus, was found in 26.67% of
the normal colonic epithelium samples, in 63.0% of the adenoma
samples, and in 100% of the primary colon adenocarcinoma samples
(Figure 5). Our results suggest that upregulation of activated STAT3
in colon carcinoma could have important implications in colorectal
cancer biology.
Table 1. Frequency of the Expression of JAK2, STAT3, and Their Activated Forms.
N STAT3, n (%) pSTAT3, n (%) JAK2, n (%) pJAK2, n (%)
Normal epithelium 15 13 (86.7%) 4 (26.7%) 9 (60%) 7 (46.7%)
Adenoma 46 41 (89.1%) 29 (63.0%) 41 (89.1%) 34 (73.9%)
Adenocarcinoma 38 38 (100%) 38 (100%) 33 (86.8%) 31 (81.6%)
Differentiation
Well 6 6 (100%) 6 (100%) 5 (83.3%) 3 (50%)
Moderate 27 27 (100%) 27 (100%) 23 (85.2%) 23 (85.2%)
Poor 3 3 (100%) 3 (100%) 3 (100%) 3 (100%)
Mucinous carcinoma 2 2 (100%) 2 (100%) 2 (100%) 2 (100%)
pSTAT3 is mostly presented in adenomas and adenocarcinomas, and a significant correlation
was found between pJAK2 immunoreactivity and the differentiation of colon adenocarcinomas
(*P < .05).
Figure 4. The functional role of JAK1, 2/STAT3 signaling on the invasive ability of CRC cell. (A) AG490 suppresses the invasion in CRC
cells at 24 hours after treatment. The migrated cell numbers were normalized to that of the negative controls. Our data demonstrated
that AG490 significantly inhibits the invasiveness of CRC cells (*P < .05). (B) CRC cells transfected with STAT3 siRNA were examined
for their invasive capability. At 48 hours posttransfection, the numbers of migrated cells significantly decreased when compared with
that of untreated cells (*P < .05). (C) Western blot analysis showed that AG490 induced a concentration-dependent upregulation of E-
cadherin, simultaneously associated with the downregulation of FAK in CRC cells at 24 hours after treatment. (D) STAT3 siRNA induced
an increase in E-cadherin at 72 hours posttransfection of the cells. However, we failed to find the FAK-level changes by STAT3 siRNA
transfection. (E) The concentrations of VEGF, MMP2, and MMP9 in AG490-treated SW1116 cells were tested by ELISA. The data are
from three individual experiments, and show reduced secretion of MMP2 and VEGF after AG490 treatment (*P < .05). (F) Effects of
STAT3 siRNA on the secretions of VEGF, MMP2, and MMP9. At 48 hours posttransfection, the concentrations of VEGF and MMP2 were
decreased compared to that of untreated cells (*P < .05). The experiment was performed three times with consistent findings.
Neoplasia Vol. 10, No. 3, 2008 JAK/STAT3 Signaling Contributes to CRC Progression Xiong et al. 293
Figure 6. Model of the possible contributions of JAK1, 2/STAT3 signaling pathway in CRC development. Proteasome-mediated prote-
olysis promotes dephosphorylation of the JAK2 kinase and, consequently, negatively regulates JAK/STAT3 signaling in CRC. Other un-
known mechanisms may also have been involved in this process. Furthermore, JAK1, 2/STAT3 signaling is implicated in many areas of
tumor progression, including cell growth, survival, invasion, and migration by regulation of gene expressions, such as Bcl-2, p16ink4a,
p21waf1/cip1, and p27kip1, E-cadherin, VEGF, and MMPs. Additionally, FAK may be a component of the JAK pathway and a downstream of
JAK, which may exert its oncogenic effects through interaction with other signal transduction pathways.
Figure 5. Immunohistochemical staining of the tissue microarray. Predominantly, cytoplasmic staining of STAT3 was frequently de-
tected in normal colonic epithelium, adenomas, and primary colon adenocarcinomas. Nevertheless, nuclear staining of pSTAT3 was
mostly presented in adenomas and adenocarcinomas. JAK2 and pJAK2 showed predominantly cytoplasm localization. Original magni-
fication, ×200.
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Activated JAK2 Correlates with the Differentiation of
Colon Adenocarcinomas
JAK2 and pJAK2 showed predominantly cytoplasm localization.
Cellular staining with anti-JAK2 antibody occurred in 60%,
89.1%, and 86.8% of the normal colonic epithelium samples, ade-
noma samples, and colon adenocarcinoma samples, respectively.
pJAK2 was observed in 46.7% of the normal tissue samples, in
73.9% of the adenoma samples, and in 81.6% of the adenocarci-
noma samples (Figure 5). Thus, adenomas and colon adenocarcinomas
showed higher expression of JAK2 and pJAK2 than normal colonic
mucosa (P < .05). Furthermore, a significant correlation was found
between pJAK2 immunoreactivity and the differentiation of colon
adenocarcinomas (Table 1).
Discussion
Despite improvements in determining the molecular mechanisms
of CRC tumorigenesis, the specific signal transduction pathways in-
volved have not been fully characterized [30]. Recently, constitutive
activation of STAT proteins has been detected frequently in several
malignant neoplasms [2,3,5,31–36]. Also, several studies have pro-
posed that STAT3 signaling may be involved in colorectal carcino-
genesis [37,38]. However, the precise role of JAK/STAT signaling
in human CRC progression has not been fully characterized. In
the present study, we provide experimental and mechanistic evi-
dences that abnormalities of JAK1, 2/STAT3 signaling contribute
to the progression of CRC.
In this study, we confirmed that AG490 induced a concentration-
dependent decrease in the JAK2 protein level in both CRC cell lines,
and this change coincided with the downregulation of pJAK2 and
pSTAT3. AG490 also decreased the levels of JAK1 and pJAK1,
but to a lesser degree than for JAK2 and pJAK2. Conversely, no sig-
nificant changes in the JAK3 and pJAK3 levels were seen as the result
of AG490 treatment. Therefore, our data suggest that whereas both
JAK1 and JAK2 may contribute to abnormalities of the JAK/STAT
signaling, JAK2 might play a more important role in CRC tumori-
genesis and progression. We also found that the proteasome inhibitor
MG132 may activate JAK2 kinase and STAT3, as MG132 efficiently
blocked the AG490-induced downregulation of pJAK2 and pSTAT3.
Therefore, we provide evidence that proteasome-mediated protein
degradation promotes dephosphorylation of the JAK2 kinase, and
consequently, negatively regulates JAK/STAT3 signaling in CRC.
Nevertheless, because MG132 is a nonspecific pharmacologic agent,
further studies are needed to substantiate these findings and to delin-
eate how proteasome degradation may regulate JAK/STAT3 signaling
in CRC. Our ongoing studies suggested that suppressor of cytokine
signaling-1 (an important negative regulator for cellular signaling
pathways such as JAK/STAT) may regulate proteasome-mediated
downregulation of JAK2 in CRC cells (data not shown).
We further evaluated the biologic significance of JAK/STAT3 ac-
tivation in the pathogenesis of CRC cells. A pharmacological JAK2
inhibitor, AG490, and STAT3 siRNA were used to selectively block
JAK/STAT3 signaling. Our results indicated that downregulation of
pJAK1, pJAK2, and pSTAT3 was associated with a gradual decrease
in viable cells. Moreover, the decrease in cell viability can be attrib-
uted to a significant increase in apoptotic cell death and cell cycle
arrest in the G1 phase. The molecular basis for cell apoptosis and cell
cycle arrest in CRC was also investigated. Treatment of CRC cells
with AG490 or STAT3 siRNA decreased Bcl-2 expression and in-
creased the expression of p16ink4a, p21waf1/cip1, and p27kip1. In addi-
tion, although previous studies have shown that STAT3 prevents
apoptosis by inducing of survivin [39,40], no change in survivin ex-
pression was seen, probably because survivin is regulated by other
pathways, such as Akt and NF-κB [41,42]. Therefore, the mecha-
nisms for induction of cell cycle arrest and apoptosis could be attri-
buted at least in part to the altered regulation of these genes.
Invasiveness is a key step that leads to metastasis resulting in poor
prognosis [43]. Therefore, it is of great value to study the molecular
mechanism of CRC invasiveness. The Matrigel invasion assay
showed that an inverse relationship between the invasiveness of
CRC cells and inhibition of JAK and STAT3 signaling, demonstrat-
ing a potential regulatory effect of JAK1, 2/STAT3 signaling on the
invasive capability of CRC cells. Because the downstream events of
the JAK/STAT3 pathway are not fully defined, we examined the ex-
pression of various migration and invasion regulatory proteins by
Western blot and ELISA analyses. Our data suggest that blockade
of JAK and STAT3 activity decreases the expression of MMP2 and
VEGF, but increases the expression of E-cadherin, suggesting that the
JAK/STAT3 pathway may be involved in the regulation of the ex-
pression of MMP2, VEGF, and E-cadherin. These results imply that
JAK/STAT3 signaling may regulate multiple processes in CRC inva-
sion. First, JAK1, JAK2, and STAT3 activation, by stimulating
MMP2 production, could induce degradation of the extracellular
matrix. Second, JAK1, 2/STAT3 signaling could regulate CRC inva-
sive capability by affecting angiogenesis. Treatment with AG490 or
STAT3 siRNA reduces VEGF secretion by CRC cells, suggesting that
the JAK/STAT3 pathway may regulate angiogenesis. Third, the JAK/
STAT3 pathway could also function in tumor metastasis and invasion
by regulating E-cadherin, a protein belonging to the family of cell-cell
adhesion molecules that plays a fundamental role in the maintenance
of cell differentiation. Thus, for the first time, we provide mechanistic
evidence that the JAK/STAT3 pathway may affect CRC metastasis by
multiple mechanisms including proliferation, enzyme-based degrada-
tion of the extracellular matrix, angiogenesis, adhesion, and migration.
Nevertheless, our findings suggest that FAK is not required for
STAT3-mediated regulation, but may be a component of the JAK
pathway downstream of JAK. Thus, these findings imply that JAK
may exert its oncogenic effects by interacting with other signal trans-
duction pathways, for instance the phosphatidylinositol-3 kinase/
protein kinase B pathway, or the activation of other STAT family
members [44,45] and not only through the activation of STAT3.
Furthermore, our data on pSTAT3 expression confirmed the re-
sults of previous studies [23,38], showing that pSTAT3 expression
is markedly increased in colon adenocarcinomas and adenomas
(100% and 63%, respectively) compared with expression in normal
colonic epithelium (26.7%), and therefore represents a significant
correlation between activated STAT3 expression and CRC tumori-
genesis. In addition, Kusaba and coworkers reported that activated
STAT3 expression is an important factor related to carcinogenesis
and CRC invasion [37]. Thus, STAT3 plays a significant role in
CRC oncogenesis and could be a potential therapeutic target for
CRC treatment. Our study also demonstrated that the expression
of pJAK2 increased with the progression of CRC (Table 1), implying
a direct relationship between pJAK2 expression and progression of
the disease. However, the samples are relatively small and further
studies are needed to validate this hypothesis.
In conclusion, this study is the first to have examined in detail the
mechanistic role of JAK/STAT3 signaling in CRC tumorigenesis and
progression (summarized in Figure 6). Our present findings strongly
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suggest that the JAK/STAT3 pathway plays a significant role in CRC
progression. We propose that JAK1, JAK2, and STAT3 are novel and
worthwhile therapeutic targets for CRC treatment, because they are
implicated in many areas of tumor progression, including cell
growth, survival, invasion, and migration. Intervention in JAK1, 2/
STAT3 signaling may have potential therapeutic value in the treat-
ment of human colorectal cancer.
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